

Special Issue

HIV-HCV Coinfection

Message from the Guest Editor

HCV is an oncogenic virus that is the primary risk factor for hepatocellular carcinoma and is also linked to extrahepatic malignancy as lymphoid cancers: while infection with HIV, in itself, is not oncogenic, it is associated with an increased risk of developing AIDS-defining cancers as well as non-AIDS-defining cancers. With this Special Issue of *Viruses*, our aim is to examine numerous topics related to this main theme. For example, we wish to explore if ongoing HCV infection, liver disease severity at antiretroviral treatment start, and achievement of sustained virological response with direct-acting antiviral treatment have an influence on long-term antiretroviral therapy efficacy; to describe an updated epidemiology of hepatic and extrahepatic malignancies in patients successfully treated for HIV-HCV infections; and to report studies discussing if the therapeutical approaches and long-term prognosis for cancer patients with HIV-HCV coinfection differ with respect to patients with only HIV infection, only HCV infection, or neither. Research articles, review articles, as well as short communications are welcome.

Guest Editor

Dr. Monica Basso

Department of Molecular Medicine, University of Padova, Padova, Italy

Deadline for manuscript submissions

closed (17 April 2021)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/58091

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

[viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).